ASCO® 2024 Insights: "Study EV-103 - Neoadjuvant Enfortumab Vedotin in Cisplatin-Ineligible MIBC Patients"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Study EV-103 - Neoadjuvant Enfortumab Vedotin in Cisplatin-Ineligible MIBC Patients"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Nataliya Mar

136 views

June 21, 2024

Comments 0

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh

2024 ASCO® Annual Meeting Insights Hub: GU Videos

ASCO® 2024 Insights: "Landscape Analysis & Oncologic Outcomes in Adv…

2024 ASCO® Annual Meeting Insights Hub

T. Stewart

11 views

1 month ago

ASCO® 2024 Prostate Cancer Take-Home Messages

2024 ASCO® Annual Meeting Insights Hub

E. Efstathiou

606 views

3 months ago

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

2024 ASCO® Annual Meeting Insights Hub

K. Mittal

364 views

4 months ago

View All

BLADDR 2024 - Hybrid Global Forum on GU Oncology

Wed, Nov 27, 2024

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.4K views

5 months ago

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views

8 months ago

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

1.4K views

5 months ago

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

7 months ago

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views

7 months ago

Updates in the Treatment and Management of Bladder Cancer

Integrity CE

M. Galsky, B. Guercio

283 views

3 months ago

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

276 views

1 month ago

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

2024 ESMO Annual Meeting Insights Hub

P. Grivas

245 views

2 months ago

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Insights from 2023 ESMO Annual Meeting

G. Sonpavde

853 views

1 year ago

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

173 views

1 month ago

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

533 views

4 months ago

Urothelial Carcinoma: New Developments

Weill Cornell Medicine Oncology & Hematology

C. Sternberg

344 views

5 months ago

ASCO® 2024 Summary: "Bladder and RCC Highlights"

2024 ASCO® Annual Meeting Insights Hub

K. Tawagi, N. Reizine

263 views

4 months ago

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

Kriti Mittal

402 views

8 months ago

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Carcino…

Insights from 2024 ASCO® GU Annual Meeting

G. Sonpavde

415 views

9 months ago

Multidisciplinary Approaches for Muscle Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

B. Bochner

198 views

4 months ago

ESMO 2023 Insights: "Phase 3 EV-302 Trial - Evaluating the Combinati…

ecancer

T. Powles

508 views

1 year ago

Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…

UCSF School of Medicine

T. Friedlander

330 views

9 months ago

New

Key GU Cancer Trials of 2024: Treatment Advances in Urothelial and P…

Yale Cancer Center

J. Kim

157 views

4 weeks ago

The Role of Biomarkers in Urothelial Carcinoma: Current Status and F…

Miami Cancer Institute Precision Oncology Symposium

S. Gupta

186 views

4 months ago

AUTOPLAY

Login

Login

Join VuMedi

ASCO® 2024 Insights: "Study EV-103 - Neoadjuvant Enfortumab Vedotin in Cisplatin-Ineligible MIBC Patients"

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

2024 ASCO® Annual Meeting Insights Hub: GU Videos

ASCO® 2024 Insights: "Landscape Analysis & Oncologic Outcomes in Adv…

ASCO® 2024 Prostate Cancer Take-Home Messages

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

Recommended

BLADDR 2024 - Hybrid Global Forum on GU Oncology

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

Recent GU Developments and Their Clinical Implications

Bladder Cancer Highlights From ASCO® 2024

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Hyperprogression in Cancer Treated With Immunotherapy

Updates in the Treatment and Management of Bladder Cancer

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

Developmental Therapeutics Highlights From ASCO® 2024

Urothelial Carcinoma: New Developments

ASCO® 2024 Summary: "Bladder and RCC Highlights"

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Carcino…

Multidisciplinary Approaches for Muscle Invasive Bladder Cancer

ESMO 2023 Insights: "Phase 3 EV-302 Trial - Evaluating the Combinati…

Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…

Key GU Cancer Trials of 2024: Treatment Advances in Urothelial and P…

The Role of Biomarkers in Urothelial Carcinoma: Current Status and F…